Position in QNCX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$253,041
+$253,041 QoQ
Shares Held
13,911
Ownership
1.37%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#6
of 25 holders
Holding Since
Sep 2020
3 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in QNCX Over Time
Shares Held
Position Value (USD)
Derivatives in QNCX
reported options exposure · as of Sep 30, 2021CallValue
$1,292,406
CallShares
70
PutValue
$6,938,662
PutShares
378
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026BOOTHBAY FUND MANAGEMENT, LLC holds $665,103,201 across 158 Biotechnology names. QNCX ranks #127 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
465,787 | $87,232,589 | |
| 2 | ABVX |
Abivax S.A.
|
563,367 | $75,074,286 | |
| 3 | EXEL |
Exelixis, Inc.
|
804,095 | $43,750,808 | |
| 4 | PCVX |
Vaxcyte, Inc.
|
534,163 | $31,050,895 | |
| 5 | COGT |
Cogent Biosciences, Inc.
|
692,825 | $26,812,327 | |
| 6 | CGEM |
Cullinan Therapeutics, Inc.
|
1,082,611 | $19,714,346 | |
| 7 | TNGX |
Tango Therapeutics, Inc.
|
500,497 | $15,645,536 | |
| 8 | AVTX |
Avalo Therapeutics, Inc.
|
702,051 | $12,973,902 |
All Filings in QNCX
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $253,041 | 13,911 | Shares | Other | 2026-08-14 | |
| 2021-09-30 | $1,292,406 | 14,100 | Call | Other | 2021-11-15 | |
| 2021-09-30 | $6,938,662 | 75,700 | Put | Other | 2021-11-15 | |
| 2020-09-30 | $229,850 | 4,597 | Shares | Other | 2020-11-16 | |
| No filing history on record for this holder in this stock. | ||||||